title: Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care.
abstract: Misconceptions and ill-founded theories can arise in all areas of science. However, the apparent accessibility of many epidemiology findings and popular interest in the subject can lead to additional misunderstandings. The article below is the third in an occasional series of short editorials highlighting some current misinterpretations of epidemiological findings. Invited authors will be given wide scope in judging the prevalence of the misconception under discussion. We hope that this series will prove instructive to cancer researchers in other disciplines as well as to students of epidemiology. Adrian L Harris and Leo Kinlen.
authors: R
authors: R
authors: Peto
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000401:mortality*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control; D057285:Precision Medicine
chemical_list: D001241:Aspirin